Our studies reveal novel mechanisms by which rh-endostatin enhances the antitumor activity of CIK cells and may provide a rational basis for combining antiangiogenesis and immunotherapy in curing advanced stage lung cancer patients. The gene discussed is COL18A1; the disease is lung cancer.